News Update: Novartis’ Drug Afinitor Met Primary Endpoint in Phase III Study (NYSE:NVS)

News Update: Novartis’ Drug Afinitor Met Primary Endpoint In Phase III Study (NYSE:NVS) – Novartis (NYSE:NVS) announced that Afinitor, a drug targeted at advanced pancreatic neuroendocrine tumors, met its primary endpoint in a Phase III study. The…